Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Etsy Inc (ETSY) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Etsy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.56 (market cap $5.07B), while Etsy Inc trades at $80.05 (market cap $7.29B). The key difference: Etsy Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Etsy Inc nearer its low. Which is the better fit depends on your goals.

ACADETSY
Market Cap
$5.07B$7.29B
Sector
HealthConsumer Cyclical
52-Week High
$29.41$86.47
52-Week Low
$20.06$44.05
Enterprise Value
$4.19B$9.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

Etsy Inc

ETSY trades at $79.42, down 1.22% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and raised its full-year outlook while announcing a 12% workforce reduction and a $2 billion share repurchase program. Revenue for 2025 was $2.88 billion with a net income margin of 5.65%, though equity remains negative at -$758.87 million due to retained earnings deficits.

The outlook is mixed: analyst consensus is a Buy with a $85.71 price target, reflecting optimism on operational efficiency and AI-driven growth, but risks include high debt, negative equity, and competitive pressures. The stock's valuation metrics like P/E of 25.15 and P/S of 3.54 suggest moderate pricing relative to peers, with cash flow stability from operations offering support amid restructuring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Etsy Inc

Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).

Read more on ETSY